REGULATION OF OSTEOBLAST GENE EXPRESSION BY CYTOKINES
Project Number5R01AR040668-03
Contact PI/Project LeaderHARRISON, JOHN R
Awardee OrganizationUNIVERSITY OF CONNECTICUT SCH OF MED/DNT
Description
Abstract Text
The clonal osteoblastic cell line MC3T3-El has been used as a model to
study the mechanisms of interleukin-1 (IL-1) and tumor necrosis
factor-alpha (TNF) action on type I collagen and prostaglandin H synthase
transcription in bone cells. Using MC3T3-El cells permanently
transfected with ColCAT 3.6, a chimeric gene consisting of 3.6 kb of
alpha1(I) flanking sequence directing transcription of the structural
thloramphenicol acetyltransferase (CAT) gene, we found that cytokines
regulate alpha1(I) promoter activity in a differentiation-dependent
manner. In cells plated at high density, which exhibit an osteoblastic
phenotype and express high levels of CAT activity, IL-1 and TNF caused
repression of alpha1(I) transcription. On the other hand, in cells
plated at low density, which are less differentiated, a stimulatory
transcriptional response to cytokines was observed. Phorbol 12-myristate
13-acetate (PMA), which mimics IL-1 and TNF actions in some systems,
repressed ColCAT 3.6 activity regardless of the differentiation state.
However, a dramatic stimulatory effect of PMA, but not cytokines, was
unmasked in differentiated cells harboring a 5'-deletion construct which
lacks the upstream basal enhancer region of the alpha1(I) promoter. The
location of cytokine and PMA response elements in the alpha1(I) promoter
will be mapped using a functional CAT assay. Initially, a series of 5'
deletion mutants will be tested for cytokine and PMA responsiveness.
ColCAT 3.6 mutants containing internal deletions will be prepared to
assess the role of downstream sequences in the presence of the intact
upstream enhancer. Putative response elements will be tested for their
ability to confer responsiveness to a heterologous thymidine kinase
promoter. Regions responsive to IL-1, TNF or PMA will be examined for
constitutive or inducible DNA-protein interactions by mobility shift,
DNase protection and methylation interference analysis. The function of
putative response elements identified by these methods will be assessed
by site-directed mutagenesis. The 5' flanking region of the PGH synthase
gene, which encodes the rate-limiting enzyme in prostaglandin
biosynthesis, will be cloned and sequenced. Regulation of PGH synthase
transcription by cytokines will be analyzed in a manner similar to that
described for the alpha1(I) promoter. These studies should contribute to
understanding the mechanisms by which cytokines alter type I collagen and
prostaglandin synthesis in bone. Thus, these studies could have
important implications for the pathogenesis of osteoporosis and bone loss
associated with chronic inflammatory disease.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
DUNS Number
022254226
UEI
H6D6JMXJXDE6
Project Start Date
15-September-1992
Project End Date
31-August-1996
Budget Start Date
01-September-1994
Budget End Date
31-August-1996
Project Funding Information for 1994
Total Funding
$139,409
Direct Costs
$94,195
Indirect Costs
$45,214
Year
Funding IC
FY Total Cost by IC
1994
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$139,409
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AR040668-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AR040668-03
Patents
No Patents information available for 5R01AR040668-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AR040668-03
Clinical Studies
No Clinical Studies information available for 5R01AR040668-03
News and More
Related News Releases
No news release information available for 5R01AR040668-03
History
No Historical information available for 5R01AR040668-03
Similar Projects
No Similar Projects information available for 5R01AR040668-03